Novo Nordisk has reaped the first harvest from its wide-ranging alliance with life sciences investor Flagship Pioneering, buying rights to two programmes from the VC’s portfolio companies Omega Therapeutics and Cellarity.The two deals are firmly within Novo Nordisk’s cardiometabolic focus – driven by semaglutide drugs Ozempic for diabetes and Wegovy for obesity – and include […]
